Key result
Bergenin improves cardiac function and attenuates remodeling and ferroptosis via YAP signaling in diabetic rats.
Why the study?
Bergenin has antioxidant, anti-inflammatory, and metabolic regulatory properties, but its cardioprotective role and underlying signaling mechanisms in diabetic cardiomyopathy remain unclear.
Does bergenin attenuate diabetic cardiomyopathy and improve cardiac function by modulating oxidative stress, YAP signaling, and ferroptosis in preclinical models?
Does bergenin attenuate diabetic cardiomyopathy and improve cardiac function by modulating oxidative stress, YAP signaling, and ferroptosis in preclinical models?
This preclinical study demonstrates that bergenin protects against diabetic cardiomyopathy by inhibiting oxidative stress and ferroptosis through the YAP signaling axis, identifying a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Should not change practice; hypothesis-generating for bergenin in diabetic cardiomyopathy, pending human trials.
AIMS Diabetes mellitus-associated cardiac dysfunction arises from metabolic imbalance, oxidative stress, inflammation, maladaptive remodeling, and impaired cardiac performance. Bergenin (BER), a naturally occurring small molecule with antioxidant, anti-inflammatory, and metabolic regulatory properties, has shown therapeutic potential; however, its role in diabetic cardiomyopathy (DCM) remains unclear. This study investigated the cardioprotective effects of BER in DCM, with particular emphasis on oxidative stress, the Hippo-Yes-associated protein (YAP), and ferroptosis signaling axis. MATERIALS AND METHODS DCM was induced in rats using a high-fat diet combined with low-dose streptozotocin (STZ). Diabetic rats received BER (25 or 50 mg/kg/day) or empagliflozin (10 mg/kg/day). Cardiac function was evaluated by echocardiography, followed by histopathological and molecular analyses. To further investigate the underlying mechanisms, H9c2 cardiomyoblasts exposed to high glucose were used for in vitro assessment of oxidative stress, Hippo-YAP signaling, and ferroptosis-related markers. KEY FINDINGS In vivo, BER treatment significantly improved cardiac function, attenuated histopathological injury, and reduced cardiomyocyte hypertrophy and fibrosis in diabetic rats. Consistent with these findings, in vitro, BER reduced reactive oxygen species generation, restored mitochondrial integrity, and prevented high glucose-induced injury in H9c2 cells. Mechanistically, BER modulated YAP signaling and suppressed ferroptosis-related changes. YAP silencing attenuated the protective effects of BER, supporting a critical role for YAP in mediating its anti-ferroptotic effects. SIGNIFICANCE These findings demonstrate that BER exerts cardioprotective effects against diabetes-associated cardiac dysfunction and provide mechanistic evidence implicating the YAP-ferroptosis axis in this protection. Further studies are warranted to establish its translational potential.
No takes yet. Share an insight, caveat, or question.
Kundu et al. (2026) studied Diabetic cardiomyopathy (in vivo rat model and in vitro H9c2 cardiomyoblasts). Bergenin vs. Empagliflozin (10 mg/kg/day) or untreated diabetic control was evaluated on Cardiac function (echocardiography), histopathological injury, oxidative stress, and ferroptosis markers. Bergenin improved cardiac function and attenuated cardiomyocyte hypertrophy, fibrosis, oxidative stress, and ferroptosis via YAP signaling in diabetic rats.
Synapse has enriched 10 related papers. Consider them for comparative context: